Methylphenidate
11 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
11
Ongoing
2
Recruiting
2
Completed
6
Sites
18
Countries
4
Endpoints
68
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 68 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 11 of 68 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
7
4
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
11 of 11
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| ADMET2Apathy in Dementia Methylphenidate Trial 2 | Methylphenidate Alzheimer’s disease | Alzheimer's disease | Ph 3 | Completed | 10 | Jul 2020 | 4 | results |
| ADMETApathy in Dementia Methylphenidate Trial (ADMET) | Methylphenidate Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 3 | Aug 2012 | 1 | results |
| NCT00254033Apathy Associated With Alzheimer's Disease | Dextroamphetamine, Methylphenidate Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 1 | Oct 2006 | 1 | |
| PRIMECombined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia | Methylphenidate Alzheimer’s disease, Vascular cognitive impairment / dementia, Mixed / unspecified dementia | Multiple dementia etiologies | Ph 2 | Recruiting | 1 | Oct 2027 | - | |
| NCT03811847A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants. | Methylphenidate Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 4 | Completed | 1 | Aug 2021 | 1 | results |
| PACTE-1Methylphenidate and Cognitive Training in Elderly | Methylphenidate Mixed / unspecified dementia | Healthy volunteers | Ph 2 | Completed | 1 | Mar 2020 | - | |
| NCT00495820Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study | Methylphenidate Alzheimer’s disease | Alzheimer's disease | Ph 4 | Completed | 1 | Mar 2010 | 2 | results |
| REACTrTMS for Apathy Clinical Trial | Methylphenidate Alzheimer’s disease, MCI / preclinical Alzheimer’s | - | Not applicable | Recruiting | 1 | Dec 2026 | - | |
| NCT01825577Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia. | Methylphenidate Mixed / unspecified dementia | Age 65-95 | Ph 4 | Terminated | 1 | Feb 2015 | - | results |
| STREAM-VCISymptomatic Treatment of Vascular Cognitive Impairment | Galantamine, Methylphenidate Vascular cognitive impairment / dementia | MMSE ≥16 | Ph 2/3 | Unknown | 1 | Dec 2016 | 2 | |
| NCT00792662Improving Function, Quality of Life, Glycemia in Diabetics With Dementia | Methylphenidate Alzheimer’s disease | mild-to-moderate AD / moderate AD dementia | Ph 4 | Withdrawn | 0 | Dec 2011 | - |
Showing 1-11 of 11 trials